Fda makena advisory committee Food and Drug Administration (FDA) voted to recommend that the FDA pursue withdrawal of approval of Makena ® (hydroxyprogesterone caproate injection), the only FDA-approved treatment to reduce the risk of preterm Oct 29, 2019 路 MAKENA® Advisory Committee Briefing Document NDA 021945 / S-023 Page 1 . C. MAKENA® (hydroxyprogesterone caproate injection) NDA 021945 / S-023 . – "ACOG is aware of the recommendation from the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to withdraw FDA approval of Makena and its generic equivalents (17-OHPC). S. For more information about the hearing and the Committee’s votes, please see the transcript posted to the Makena docket at Docket (FDA-2020-N-2029); FDA-2020-N-2029-0376; and FDA-2020-N-2029-0377. October 29, 2019. ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE . Apr 7, 2023 路 The more recent advisory committee meeting on the drug was in October, when the FDA’s independent Obstetrics, Reproductive and Urologic Drugs Advisory Committee voted 14-1 that the drug should Washington, D. Advisory Committee Meeting . Oct 20, 2022 路 Following a 3 day meeting, the Food and Drug Administration’s (FDA) Obstetrics, Reproductive, and Urologic Drugs Advisory Committee voted to recommend that the FDA pursue withdrawal of Makena Oct 18, 2022 路 MAKENA ADVISORY COMMITTEE KICKS OFF — The FDA convened a two-and-a-half day advisory committee meeting Monday by stating in no uncertain terms that Makena, an injectable drug marketed as Oct 19, 2022 路 Zug, Switzerland, 19 October 2022 – Covis Pharma Group (the “Company”), today reported that the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee to the U. Bone, Reproductive, and Urologic Drugs . 1100 Winter Street. The committee's recommendation was based on results from the postmarket confirmatory trial data in the PROLONG study, released in October 2019. AMAG Pharmaceuticals, Inc.